|

Bispecific CD80-lgG4Fc-IL-2v Fusion Protein GI-102 Clinical Trials

1 actively recruiting trial across 1 location

Also known as: GI 102, GI-102, GI102

Pipeline

Phase 2: 1

Top Sponsors

  • Mayo Clinic1

Indications

  • Progressive Gliosarcoma1
  • Progressive Astrocytoma, IDH-Mutant, Grade 41
  • Resectable Astrocytoma1
  • Resectable Glioblastoma1
  • Recurrent Astrocytoma, IDH-Mutant, Grade 41

Rochester, Minnesota1 trial

GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma

Mayo Clinic in Rochester

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.